Kala Pharmaceuticals Inc (KALA)

$KALA 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

CEO

Mark Iwicki

Exchange

NASDAQ

Website

kalarx.com

$11M

Total Revenue

188

Employees

$187M

Market Capitalization

-1.48

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 19327 2239 2.87 15.52 43.40
Organon & Co. OGN 8644 7891 -4.46 4.95 22.06
Arvinas Inc ARVN 4342 21 8.14 -26.29 -782.93
Tilray Inc TLRY 3286 513 1.23 -9.74 -71.61
ATAI Life Sciences N.V. ATAI 2545 20 5.35 -11.65 -932.88
Cronos Group Inc CRON 2114 57 1.33 -14.64 -258.59
Usana Health Sciences Inc USNA 1837 1254 4.18 13.23 11.09
Phathom Pharmaceuticals Inc PHAT 1178 7.99 -7.35 None
Fulcrum Therapeutics Inc FULC 925 15 11.21 -12.53 -481.07
Intersect ENT Inc XENT 899 103 21.80 -13.10 -66.55
Phibro Animal Health Corp. PAHC 888 833 3.68 16.16 6.53
Edgewise Therapeutics Inc EWTX 848 2.87 -31.45 None
Pliant Therapeutics Inc PLRX 657 13 2.69 -7.66 -613.56
Cyteir Therapeutics Inc CYT 637 3.42 -22.04 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 467 10 2.52 -8.53 -551.28
Chromadex Corp CDXC 433 62 10.92 -18.30 -37.51
Rain Therapeutics Inc RAIN 404 413 2.50 -13.27 123.20
Provention Bio Inc PRVB 400 2.68 -3.12 None
Evolus Inc EOLS 321 77 4.24 -2.15 -171.53
Verrica Pharmaceuticals Inc VRCA 316 12 6.41 -8.69 -301.45
Terns Pharmaceuticals Inc TERN 263 1.46 -7.62 None
Adicet Bio Inc ACET 230 9 1.00 -4.09 -603.06
Milestone Pharmaceuticals Inc MIST 222 15 1.25 -7.50 -215.93
Kaleido Biosciences Inc KLDO 222 1 4.94 -2.49 None
LifeMD Inc LFMD 201 64 -28.62 -1.44 -133.55
Kala Pharmaceuticals Inc KALA 187 11 2.42 -1.48 None
Osmotica Pharmaceuticals Plc OSMT 181 190 2.64 -1.95 -47.85
Citius Pharmaceuticals Inc CTXR 177 2.21 -7.70 None
scPharmaceuticals Inc SCPH 162 119 2.38 -5.36 -27.05
Aquestive Therapeutics Inc AQST 146 42 -3.02 -2.27 -152.73
Eton Pharmaceuticals Inc ETON 123 15 6.11 -10.06 -74.52
Odonate Therapeutics Inc ODT 117 1.47 -1.00 None
Eyenovia Inc EYEN 113 6 12.86 -5.77 -324.94
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Opiant Pharmaceuticals Inc OPNT 90 37 2.71 -86.08 -3.06
Natural Alternatives Internati NAII 89 169 1.26 10.07 5.68
VYNE Therapeutics Inc VYNE 72 16 1.08 3.27 -554.66
India Globalization Capital In IGC 67 0 2.39 -7.65 -981.18
Mannatech Inc MTEX 66 158 2.63 10.35 4.22
Acasti Pharma Inc ACST 42 0 1.81 -2.11 -611.47
Shineco Inc TYHT 36 14 1.85 -1.78 -159.60
Assertio Holdings Inc ASRT 33 117 0.45 -0.58 -38.05
Reviva Pharmaceuticals Holding RVPH 30 1.64 -4.74 None
Baudax Bio Inc BXRX 28 1 -11.98 0.84 None
Nabriva Therapeutics Plc NBRV 28 12 0.83 -0.47 -452.55
Bio-Path Holdings Inc BPTH 28 0 1.29 -2.68 18.96
Timber Pharmaceuticals Inc TMBR 26 0 11.39 0.88 -527.55
Trevi Therapeutics Inc TRVI 26 1.67 -0.74 None
Lexaria Bioscience Corp LEXX 25 1 3.49 -6.45 -445.15
Hoth Therapeutics Inc HOTH 22 1.85 -2.29 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.13 -2.04 -31.96

Why Should You Consider Adding Kala Pharmaceuticals Inc. (KALA) To Your Portfolio?

10d ago, source: marketingsentinel

Kala Pharmaceuticals Inc. (NASDAQ:KALA) has a beta value of 0.39 and has seen 1.45 million shares traded in the last trading ...

Do Kala Pharmaceuticals Inc. (KALA) beta value of 0.39 signposts another twist?

10d ago, source: investchronicle

Kala Pharmaceuticals Inc. (KALA) is priced at $3.26 after the most recent trading session. At the very opening of the session ...

Kala Pharmaceuticals Inc. (NASDAQ:KALA) 20.06% Above Its 52-Week Low, How Long Will It Keep Rising?

7d ago, source: marketingsentinel

In last trading session, Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw 1.01 million shares changing hands with its beta currently measuring 0.39. Company’s recent per share price level of $3.34 trading ...

Is Kala Pharmaceuticals Inc. (NASDAQ: KALA) A Great Stock To Invest In?

9d ago, source: stocksregister

Kala Pharmaceuticals Inc. (NASDAQ:KALA) traded at $3.28 at close of the session on Tuesday, September 07, made an upward move of 0.61% on its previous day’s price. Looking at the stock we see that its ...

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

10d ago, source: Yahoo Finance

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on ...

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

10d ago, source: Yahoo Finance

About Kala Pharmaceuticals, Inc. Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

29d ago, source: The Globe and Mail

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced ...

Your Portfolio